ArticleApplied health economics and health policy2026
Cost-Effectiveness and Public Health Impact of Newborn Screening for Spinal Muscular Atrophy in France.
Article in Applied health economics and health policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSpinal muscular atrophy (SMA) was recently included in the French national newborn screening (NBS) program. The aim of this study was to assess the public health impact and cost-utility of SMA NBS in the French setting. MATERIALS AND
methodsA cost-utility model combining a decision tree with a lifetime state transition model (six health states) was adapted from a previous model. The model simulated a cohort of 700,000 newborns annually, aligned with French birth statistics. Clinical inputs were derived from SMA trials. Cost and utility estimates reflected French healthcare system data and societal burden studies. Analyses were conducted from a societal perspective, with key outcomes including the incremental cost-utility ratio (ICUR), quality-adjusted life years (QALYs), and incremental net monetary benefit (INMB). Deterministic, probabilistic, and scenario analyses were performed.
resultsWith NBS, 66.5 patients are expected to be treated presymptomatically each year. At age 15 years, mortality is reduced to 2% in the NBS arm compared with 26% without screening; 94% of patients will retain the ability to sit or walk versus 38% without NBS. NBS is a dominant strategy versus no NBS, with lower costs (- 233.9 million [M] euros) and higher QALYs (+ 1586). The INMB was 265.6M € at a 20,000 €/QALY threshold. Results were robust across all sensitivity and scenario analyses. LIMITATIONS: Key limitations include uncertainty in long-term treatment effects, exclusion of SMA type 0 and 4 from the model, and limited data on long-term outcomes of presymptomatically treated patients.
conclusionsNBS for SMA in France offers significant clinical and economic value, supporting its national implementation.
Indexed as
Identifiers
41811688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.